A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

NCT02588131 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Pleural Mesothelioma
Peritoneal Mesothelioma

Interventions

DRUG: tremelimumab plus MEDI4736

Sponsor

Italian Network for Tumor Biotherapy Foundation

Collaborators

[object Object]